Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Under Armour reports today with every major positioning signal tilted against it — short interest near the highest in years, options at their most defensive in 52 weeks, and the stock down 27% in a month.
Short sellers have built a substantial position heading into the print. Nearly a quarter of the free float — 24.2% — is currently short, up 1.4% on the week even after a sharp 23% decline over the past month. That month-long decline reflects a meaningful unwind from even more extreme levels in July, when shorts approached 60 million shares before falling to the current ~45.8 million. The borrow market is not signalling a squeeze: availability runs near 64%, cost to borrow holds at a negligible 0.54%, and both metrics suggest the lending pool has ample room. Shorts face no pressure to cover on borrow costs alone. ORTEX's short score of 73.5 ranks UAA in the 97th percentile for short pressure — the factor score on short rank sits at just 3 out of 100.
Options traders are equally bearish. The put/call ratio hit 2.76 on Tuesday — the highest reading in the past 52 weeks — compared to a 20-day average of 2.56. That is already an elevated baseline, meaning UAA options have consistently skewed toward downside protection for weeks. The step-up to the annual peak on the eve of earnings amplifies the signal: whoever is buying protection is doing so at maximum urgency. The stock fell 4.7% on Tuesday alone, leaving it at $5.12, and the 1-month loss of 27% has done little to attract dip-buyers ahead of the print.
The analyst community turned more negative in the days following the previous quarterly report. Barclays downgraded to Underweight on August 11 while holding its $5.00 target — essentially a price-to-current-stock signal with no upside embedded. UBS, the lone bull on the Street, lowered its Buy target from $10 to $9. The consensus mean of $6.40 implies modest upside from current levels, but 18 of the covered analysts rate the stock Hold and two rate it Underperform, with no Buy upgrades forthcoming. The bull case — restructuring savings, margin recovery, lifestyle expansion — collides directly with the bear case: weak e-commerce traffic, elevated inventory, high SG&A, and a promotional environment that keeps full-price sell-through under pressure. EPS momentum ranks in the 7th percentile over 30 days, and the analyst recommendation differential sits at just 2 out of 100.
Institutional ownership adds an unusual wrinkle. Fairfax Financial and its affiliated entities hold roughly 15.7% of shares, and the data shows a pattern of steady buying stretching back to late 2025 — including a $59 million purchase in December. The CFO also bought approximately $100,000 worth of stock on August 11, the same day Barclays downgraded. The last two earnings prints both produced sharp declines: the stock fell around 8-10% on the day and shed 16-21% in the five sessions that followed. Availability tightened sharply through mid-August before easing somewhat, suggesting some short covering occurred into that prior print before new positions were rebuilt.
Today's print will test whether the restructuring narrative can survive another guidance cut — and whether any margin progress is enough to break a pattern of post-earnings selling that has persisted through every recent report.
See the live data behind this article on ORTEX.
Open UAA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
